摘要
目的:探讨金属蛋白酶2组织抑制剂(TIMP-2)在乳腺癌组织中的表达特点及其与临床病理参数的关系。方法:采用免疫组织化学SP法,检测62例乳腺癌组织中TIMP-2的表达情况。结果:乳腺癌组织中TIMP-2阳性表达率为64.52%。TIMP-2阳性表达率在≤50岁年龄组(51.52%)比>50岁患者年龄组阳性率(79.31%)明显偏低(P<0.05)。浸润性导管癌的阳性表达率(71.15%)明显高于导管内癌局部浸润的阳性表达率(30.00%)(P<0.05)。无淋巴结转移组阳性率(78.38%)明显高于有淋巴结转移组(44.00%)(P<0.05)。TIMP-2阳性表达与癌的左右乳分布及临床分期没有显著性差异(P>0.05)。结论:在乳腺癌组织中TIMP-2表达降低,可能促进了乳腺癌的浸润进展及转移,金属蛋白酶抑制剂的研治将为乳腺癌的临床治疗开辟新途径。
Objective:To explore the expression characteristic of tissue inhibitor of metalloproteinase(TIMP)-2 in breast carcinomas and its relationship to pathoclinical parameters.Methods:TIMP-2 expression was detected by SP immunohistochemistry in 62 cases of breast carcinoma tissues.Results:The positive rate of TIMP-2 expression in breast carcinoma tissues was 64.52%.The positive rate in ≤50 year old age group(51.52%) was obviously lower than >50 year old group(79.31%)(P<0.05).Expression rate in invasive duct...
出处
《陕西医学杂志》
CAS
北大核心
2008年第2期169-171,共3页
Shaanxi Medical Journal
关键词
乳腺肿瘤
免疫组织化学
金属蛋白酶2组织抑制剂
Breast neoplasms Immunohistochemistry Tissue inhibitor-of metalloproteinase-2
